Country: Canada
Language: English
Source: Health Canada
NORTRIPTYLINE (NORTRIPTYLINE HYDROCHLORIDE)
APOTEX INC
N06AA10
NORTRIPTYLINE
25MG
CAPSULE
NORTRIPTYLINE (NORTRIPTYLINE HYDROCHLORIDE) 25MG
ORAL
100/500
Prescription
TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0102630001; AHFS:
APPROVED
2021-12-02
_APO-NORTRIPTYLINE (_ _Nortriptyline Hydrochloride Capsules) _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-NORTRIPTYLINE Nortriptyline Hydrochloride Capsules Capsules, 10 mg and 25 mg, Oral USP Antidepressant APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: JUN 27, 1996 Date or Revision: JUN 07, 2023 Submission Control Number: 275780 _APO-NORTRIPTYLINE (_ _Nortriptyline Hydrochloride Capsules) _ _Page 2 of 32_ RECENT MAJOR LABEL CHANGES N/A N/A TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..................................................................................................... 2 TABLE OF CONTENTS ....................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................... 4 1 INDICATION ....................................................................................................................................... 4 1.1 Pediatrics .................................................................................................................................... 4 1.2 Geriatrics .................................................................................................................................... 4 2 CONTRAINDICATIONS .............................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS ................................................................................. 4 4 DOSAGE AND ADMINISTRATION .............................................................................................. 4 4.1 Dosing Considerations ............................................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ........... Read the complete document